5-(N,N-dimethylsulafmoyl)-2-fluorobenzoic acid | 91103-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(N,N-dimethylsulafmoyl)-2-fluorobenzoic acid
• 英文别名: 5-(N,N-dimethylsulfamoyl)-2-fluorobenzoic acid；5-dimethylsulfamoyl-2-fluorobenzoic acid；5-Dimethylsulfamoyl-2-fluoro-benzoic acid；5-(dimethylsulfamoyl)-2-fluorobenzoic acid
• CAS: 91103-94-5
• 化学式: C₉H₁₀FNO₄S
• mdl: MFCD06355944
• 分子量: 247.247
• InChiKey: SPLPERBFJNXJRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(N,N-dimethylsulafmoyl)-2-fluorobenzoic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 N-<(4-benzyl-2-morpholinyl)methyl>-5-(N,N-dimethylsulfamoyl)-2-(methylamino)benzamide
  参考文献：
  名称：

  Synthesis and Gastroprokinetic Activity of 2-Amino-N-((4-benzyl-2-morpholinyl)methyl)benzamide Derivatives.

  摘要：

  2-烷氧基-4-氨基-N-[(4-苄基-2-吗啉基)甲基]-5-氯苯甲酰胺已被确定为一系列选择性强效胃动力药的有趣成员。我们合成了一系列新的 2-氨基-和 2-（取代氨基）-N-[（4-苄基-2-吗啉基）甲基]苯甲酰胺（13-35），并对这些化合物进行了研究，以确定它们与带有 2-烷氧基的 2-吗啉基苯甲酰胺 1 相比是否具有优势。胃动力活性普遍降低，但有几个化合物显示出相对较强的活性，可与标准药物甲氧氯普胺相媲美。N-[(4-Benzyl-2-morpholinyl)methyl]-4-chloro-2-[(4-chlorobenzoyl)amino]benzamide (32) 在该系列中显示出最强的活性。

  DOI：

  10.1248/cpb.43.582

文献信息

• Substituted benzamide derivatives, for enhancing gastrointestinal
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04870074A1

  公开（公告）日：1989-09-26

  Compounds of the formula: ##STR1## wherein R is hydrogen, alkoxycarbonyl, benzyloxycarbonyl, heteroarylalkyl, phenylalkenyl, or --T--(Y).sub.p --R.sub.6 (wherein T is single bond or alkylene, Y is oxygen, sulfur or carbonyl, R.sub.6 is phenyl, substituted phenyl, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T is single bond, p is 0); R.sub.1 is halogen, hydroxy, alkoxy, cycloalkyloxy, alkenyloxy, alkynyloxy, alkoxy interrupted by oxygen or carbonyl, alkylthio, amino, monosubstituted amino, or a substituted alkoxy; R.sub.2 is hydrogen; R.sub.3 is hydrogen, halogen, amino, alkylamino, dialkylamino, alkanoylamino, or nitro; R.sub.4 is hydrogen, halogen, nitro, sulfamoyl, alkylsulfamoyl, or dialkylsulfamoyl; or any two adjacent groups of the R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may combine to form alkylenedioxy, and the remaining two groups are each hydrogen; R.sub.5 is hydrogen or alkyl; X is alkylene; m and n are each 1 or 2; provided that at least one of the groups R.sub.2, R.sub.3 and R.sub.4 is other than hydrogen, and acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastrointestinal motility enhancing activity.

  式中R为氢、烷氧羰基、苄氧羰基、杂环烷基、苯基烯基，或--T--(Y).sub.p --R.sub.6（其中T为单键或烷基，Y为氧、硫或羰基，R.sub.6为苯基、取代苯基、萘基或二苯甲基，p为0或1，但当T为单键时，p为0）；R.sub.1为卤素、羟基、烷氧基、环烷氧基、烯基氧基、炔基氧基、被氧或羰基中断的烷氧基、烷基硫醚、氨基、单取代氨基，或取代烷氧基；R.sub.2为氢；R.sub.3为氢、卤素、氨基、烷基氨基、二烷基氨基、烷酰氨基，或硝基；R.sub.4为氢、卤素、硝基、磺酰胺基、烷基磺酰胺基，或二烷基磺酰胺基；或R.sub.1、R.sub.2、R.sub.3和R.sub.4中的任意两个相邻基团可结合形成亚烷二氧基，其余两个基团各为氢；R.sub.5为氢或烷基；X为烷基；m和n各为1或2；但R.sub.2、R.sub.3和R.sub.4中至少有一个基团不是氢，以及其酸盐、季铵盐和N-氧化物衍生物，其制备方法，以及含有它们的药物组合物。所述化合物、盐及其N-氧化物衍生物表现出优异的胃肠动力增强活性。
• [EN] COMPOUNDS ACTIVE TOWARDS BROMODOMAINS<br/>[FR] COMPOSÉS ACTIFS ENVERS DES BROMODOMAINES
  申请人：NUEVOLUTION AS

  公开号：WO2016016316A1

  公开（公告）日：2016-02-04

  Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

  揭示了针对溴结构域的化合物，含有这些化合物的药物组合物以及这些化合物在治疗中的用途。
• Substituted aza bicycloalkyl derivatives with dopamine antagonist activity
  申请人：BEECHAM GROUP PLC

  公开号：EP0102195A2

  公开（公告）日：1984-03-07

  Compounds of formula (I):, or a pharmaceutically acceptable salt and/or N-oxide and/or a solvate thereof: wherein: one of X and Y is CO and the other is NH; R4 is a group: or wherein: p and q each independently are 0 to 2; Z is O or S; n is O or 1; one of R6 and R7 when n=0 is C1-4 alkoxy, C1-4 alkoxycarbonyl, hydroxy or C1-4 alkyl optionally substituted by hydroxy, C1-4 alkoxy or C1-4 acyloxy, and the other is hydrogen or C1-4 alkyl or one of R6, R7 and R8 when n=1 is C1-4 alkyl and the other two are the same or different and are hydrogen or C1-4 alkyl; R5 is C1-7 alkyl, - (CH2)sR10,s being 0 to 2 and R10 being C3-8 cydoatkyl. -(CH2ytR11,t being 1 or 2 and R11 being thienyl or phenyl optionally substituted by one or two substituents selected from C1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy and C1-4 alkyl optionally substituted by hydroxy, C1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrotysable acytoxy; R, is carboxylic C1-7 acyl, carboxylic C1-7 acytamino optionally N-substituted by C1-6 alkyl, carboxylic C1-7 acyloxyamino, C1-6 alkylsulphonyl, C1-6 alkylsulphinyl, halogen, C1-6 alkyf, C3-6 cycloalkyl or amino optionally substituted by one or two groups selected from C1-6 alkyl, C3-8 cyetoalkyt, C3-8 cydoatkyt C1-4 alkyl, phenyl or phenyl C1-4 aftryl groups any of which phenyl moieties may be sufsstituted by one or more halogen, triftuoromethyl, C1-6 alkoxy or nitro groups, or amino-disubstituted by C4-5 polymethylene; and R2 and R3 are the same or different and are hydrogen, halogen, trifluoromethyl, C1-6 alkoxy, C1-6 alkytthio, carboxylic C1-7 acyl, carboxylic C1-7 acylamino, C1-6 alkylsulphonyl, C1-6 alkylsulphinyl, nitro or NR12R13, NR12R13CO, NR12R13SO2, or C1-6 alkyl-SO2NR14, NR12R13SO2NR14 wherein R12 and R,3 are the same or different and are hydrogen, C1-6 alkyl, C3-8 cycloalkyl, phenyl or phenyl C1-4 alkyl groups any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C1-6 alkoxy or nitro groups, or R12 and R,3 together form C4-5 polymethylene, and R,4 is hydrogen or C1-6 alkyl having anti-hypertensive activity, a process for their preparation and their use as pharmaceuticals.

  式（I）化合物：或其药学上可接受的盐和/或 N-氧化物和/或溶液： 其中：X 和 Y 中的一个是 CO，另一个是 NH；R4 是一个基团： 或 其中 p 和 q 各自独立地为 0 至 2； Z 是 O 或 S n 是 O 或 1； 当 n=0 时，R6 和 R7 中的一个是 C1-4 烷氧基、C1-4 烷氧羰基、羟基或任选被羟基、C1-4 烷氧基或 C1-4 丙烯酸氧基取代的 C1-4 烷基，另一个是氢或 C1-4 烷基；或当 n=1 时，R6、R7 和 R8 中的一个是 C1-4 烷基，另两个相同或不同，并且是氢或 C1-4 烷基； R5 为 C1-7 烷基，-(CH2)sR10,s 为 0 至 2，R10 为 C3-8 环烷基。-( ytR11,t 为 1 或 2，R11 为噻吩基或苯基，可任选被一个或两个取代基取代，这些取代基选自 C1-4 烷氧基、三氟甲基、卤素、硝基、羧基、酯化羧基和可任选被羟基、C1-4 烷氧基、羧基、酯化羧基或体内可水解的酰氧基取代的 C1-4 烷基； R，是由 C1-6 烷基任选 N-取代的羧基 C1-7 乙酰基、羧基 C1-7 乙酰氨基、C1-6 烷基磺酰基、C1-6 烷基亚磺酰基、卤素、C1-6 烷基、C3-6 环烷基或由选自 C1-6 烷基的一个或两个基团任选取代的氨基、C3-8 环烷基、C3-8 环烷基 C1-4 烷基、苯基或苯基 C1-4 芳基，其中任何苯基可被一个或多个卤素、三氟甲基、C1-6 烷氧基或硝基取代，或被 C4-5 聚亚甲基氨基取代；和 R2 和 R3 相同或不同，并且是氢、卤素、三氟甲基、C1-6 烷氧基、C1-6 烷硫基、C1-7 羧酰基、C1-7 羧酰基氨基、C1-6 烷基磺酰基、C1-6 烷基亚磺酰基、硝基或 NR12R13、NR12R13CO、NR12R13SO2 或 C1-6 烷基-SO2NR14、NR12R13SO2NR14，其中 R12 和 R,3 相同或不同，并且是氢、C1-6 烷基、C3-8 环烷基、C1-6 烷氧基、C1-6 烷硫基、C1-7 羧酰基、C1-7 羧氨基、C1-6 烷基磺酰基、C1-6 烷基亚磺酰基、硝基或 NR12R13、NR12R13CO、NR12R13SO2 或 C1-6 烷基-SO2NR14、C3-8环烷基、苯基或苯基C1-4烷基，其中任一苯基可被一个或多个卤素、三氟甲基、C1-6烷氧基或硝基取代，或R12和R,3共同形成C4-5聚亚甲基，R,4为氢或C1-6烷基，具有抗高血压活性，其制备方法及其作为药物的用途。
• Compounds active towards bromodomains
  申请人：NUEVOLUTION A/S

  公开号：US10752640B2

  公开（公告）日：2020-08-25

  Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

  所公开的是针对溴化多聚酶的化合物、含有这些化合物的药物组合物以及这些化合物在治疗中的用途。
• Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：EP0243959B1

  公开（公告）日：1992-08-19